PAVmed Inc
NASDAQ:PAVM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
PAVmed Inc
PP&E Gross
PAVmed Inc
PP&E Gross Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Gross | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PAVmed Inc
NASDAQ:PAVM
|
PP&E Gross
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
PP&E Gross
$4.5B
|
CAGR 3-Years
16%
|
CAGR 5-Years
13%
|
CAGR 10-Years
12%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
PP&E Gross
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Stryker Corp
NYSE:SYK
|
PP&E Gross
$4.4B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
14%
|
|
|
Abbott Laboratories
NYSE:ABT
|
PP&E Gross
$11.8B
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
PP&E Gross
$5.5B
|
CAGR 3-Years
31%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
PAVmed Inc
Glance View
PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. The company is headquartered in New York City, New York and currently employs 89 full-time employees. The company went IPO on 2016-07-27. The firm has four operating divisions. GI Health division includes EsoGuard, EsoCheck and EsoCure. EsoGuard and EsoCheck have been developed to provide non-invasive, patient-friendly screening test for the early detection of adenocarcinoma of the esophagus (EAC) and Barrett's Esophagus (BE), including dysplasia and related pre-cursors to EAC in patients with chronic gastroesophageal reflux (GERD). EsoCure is in development as an Esophageal Ablation Device with the intent to allow a clinician to treat dysplastic BE before it can progress to EAC. Minimally Invasive Interventions division offers CarpX, a minimally invasive surgical device for carpal tunnel syndrome. Infusion Therapy division includes PortIO, which is an implantable, intraosseous vascular access device, and NextFlo, which is a disposable, infusion platform technology that includes intravenous infusion sets and disposable infusion pumps.
